Cargando…

Gene-Therapeutic Strategies Targeting Angiogenesis in Peripheral Artery Disease

The World Health Organization announced that cardiovascular disease is the number one cause of death globally, representing 31% of all global deaths. Coronary artery disease (CAD) affects approximately 5% of the US population aged 40 years and older. With an age-adjusted prevalence of approximately...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanada, Fumihiro, Taniyama, Yoshiaki, Muratsu, Jun, Otsu, Rei, Shimizu, Hideo, Rakugi, Hiromi, Morishita, Ryuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024305/
https://www.ncbi.nlm.nih.gov/pubmed/29601487
http://dx.doi.org/10.3390/medicines5020031
_version_ 1783336034258386944
author Sanada, Fumihiro
Taniyama, Yoshiaki
Muratsu, Jun
Otsu, Rei
Shimizu, Hideo
Rakugi, Hiromi
Morishita, Ryuichi
author_facet Sanada, Fumihiro
Taniyama, Yoshiaki
Muratsu, Jun
Otsu, Rei
Shimizu, Hideo
Rakugi, Hiromi
Morishita, Ryuichi
author_sort Sanada, Fumihiro
collection PubMed
description The World Health Organization announced that cardiovascular disease is the number one cause of death globally, representing 31% of all global deaths. Coronary artery disease (CAD) affects approximately 5% of the US population aged 40 years and older. With an age-adjusted prevalence of approximately 12%, peripheral artery disease (PAD) affects at least 8 to 12 million Americans. Both CAD and PAD are caused by mainly atherosclerosis, the hardening and narrowing of arteries over the years by lipid deposition in the vascular bed. Despite the significant advances in interventions for revascularization and intensive medical care, patients with CAD or PAD who undergo percutaneous transluminal angioplasty have a persistent high rate of myocardial infarction, amputation, and death. Therefore, new therapeutic strategies are urgently needed for these patients. To overcome this unmet need, therapeutic angiogenesis using angiogenic growth factors has evolved in an attempt to stimulate the growth of new vasculature to compensate for tissue ischemia. After nearly 20 years of investigation, there is growing evidence of successful or unsuccessful gene therapy for ischemic heart and limb disease. This review will discuss basic and clinical data of therapeutic angiogenesis studies employing angiogenic growth factors for PAD patients and will draw conclusions on the basis of our current understanding of the biological processes of new vascularization.
format Online
Article
Text
id pubmed-6024305
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-60243052018-07-05 Gene-Therapeutic Strategies Targeting Angiogenesis in Peripheral Artery Disease Sanada, Fumihiro Taniyama, Yoshiaki Muratsu, Jun Otsu, Rei Shimizu, Hideo Rakugi, Hiromi Morishita, Ryuichi Medicines (Basel) Review The World Health Organization announced that cardiovascular disease is the number one cause of death globally, representing 31% of all global deaths. Coronary artery disease (CAD) affects approximately 5% of the US population aged 40 years and older. With an age-adjusted prevalence of approximately 12%, peripheral artery disease (PAD) affects at least 8 to 12 million Americans. Both CAD and PAD are caused by mainly atherosclerosis, the hardening and narrowing of arteries over the years by lipid deposition in the vascular bed. Despite the significant advances in interventions for revascularization and intensive medical care, patients with CAD or PAD who undergo percutaneous transluminal angioplasty have a persistent high rate of myocardial infarction, amputation, and death. Therefore, new therapeutic strategies are urgently needed for these patients. To overcome this unmet need, therapeutic angiogenesis using angiogenic growth factors has evolved in an attempt to stimulate the growth of new vasculature to compensate for tissue ischemia. After nearly 20 years of investigation, there is growing evidence of successful or unsuccessful gene therapy for ischemic heart and limb disease. This review will discuss basic and clinical data of therapeutic angiogenesis studies employing angiogenic growth factors for PAD patients and will draw conclusions on the basis of our current understanding of the biological processes of new vascularization. MDPI 2018-03-30 /pmc/articles/PMC6024305/ /pubmed/29601487 http://dx.doi.org/10.3390/medicines5020031 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sanada, Fumihiro
Taniyama, Yoshiaki
Muratsu, Jun
Otsu, Rei
Shimizu, Hideo
Rakugi, Hiromi
Morishita, Ryuichi
Gene-Therapeutic Strategies Targeting Angiogenesis in Peripheral Artery Disease
title Gene-Therapeutic Strategies Targeting Angiogenesis in Peripheral Artery Disease
title_full Gene-Therapeutic Strategies Targeting Angiogenesis in Peripheral Artery Disease
title_fullStr Gene-Therapeutic Strategies Targeting Angiogenesis in Peripheral Artery Disease
title_full_unstemmed Gene-Therapeutic Strategies Targeting Angiogenesis in Peripheral Artery Disease
title_short Gene-Therapeutic Strategies Targeting Angiogenesis in Peripheral Artery Disease
title_sort gene-therapeutic strategies targeting angiogenesis in peripheral artery disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024305/
https://www.ncbi.nlm.nih.gov/pubmed/29601487
http://dx.doi.org/10.3390/medicines5020031
work_keys_str_mv AT sanadafumihiro genetherapeuticstrategiestargetingangiogenesisinperipheralarterydisease
AT taniyamayoshiaki genetherapeuticstrategiestargetingangiogenesisinperipheralarterydisease
AT muratsujun genetherapeuticstrategiestargetingangiogenesisinperipheralarterydisease
AT otsurei genetherapeuticstrategiestargetingangiogenesisinperipheralarterydisease
AT shimizuhideo genetherapeuticstrategiestargetingangiogenesisinperipheralarterydisease
AT rakugihiromi genetherapeuticstrategiestargetingangiogenesisinperipheralarterydisease
AT morishitaryuichi genetherapeuticstrategiestargetingangiogenesisinperipheralarterydisease